A Phase I/II, Multi-part, Open-label, Multicenter, First-in-human Trial to Evaluate Safety, Tolerability, Immunogenicity, and Signals of Efficacy of JJP-1008 as Monotherapy and in Combination in Participants with Advanced, Unresectable Skin Melanoma and Other Solid Tumors
Sponsor: JJP BIOLOGICS Sp. z o.o.
Phase: 1, 2
Disease: Cutaneous melanoma, Non-small cell lung cancer, Small-cell lung cancer, Microsatellite-stable colorectal cancer, Hepatocellular carcinoma, Renal cell carcinoma, Gastric carcinoma, Esophageal carcinoma, Gastroesophageal junction carcinoma, Breast cancer, Bladder cancer, Prostate cancer
EU trial number: 2026-527193-36-00
Population: Adults ≥18 years with ECOG 0–1 and progressive, locally advanced unresectable or metastatic cutaneous melanoma or specified other solid tumors, after standard therapies have failed or are unsuitable; dose expansion requires RECIST/iRECIST-measurable disease and prior systemic treatment.
Register Investigator Interest
Interested in offering this trial to suitable patients?